

## MIT Open Access Articles

*A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy*

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

**Citation:** Cannell, Ian G. et al. "A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy." *Cancer Cell* 28.5 (2015): 623–637.

**As Published:** <http://dx.doi.org/10.1016/j.ccell.2015.09.009>

**Publisher:** Elsevier

**Persistent URL:** <http://hdl.handle.net/1721.1/105498>

**Version:** Author's final manuscript: final author's manuscript post peer review, without publisher's formatting or copy editing

**Terms of use:** Creative Commons Attribution-NonCommercial-NoDerivs License





Published in final edited form as:

*Cancer Cell*. 2015 November 9; 28(5): 623–637. doi:10.1016/j.ccell.2015.09.009.

## A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of *p53*-defective Tumors to Chemotherapy

Ian G Cannell<sup>1</sup>, Karl A Merrick<sup>#1</sup>, Sandra Morandell<sup>#1,#</sup>, Chang-Qi Zhu<sup>#2</sup>, Christian J Braun<sup>1</sup>, Robert A Grant<sup>1</sup>, Eleanor R Cameron<sup>1</sup>, Ming-Sound Tsao<sup>2</sup>, Michael T Hemann<sup>1</sup>, and Michael B Yaffe<sup>1,3,4,5,6</sup>

<sup>1</sup> David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

<sup>2</sup> Princess Margaret Cancer Centre, University Health Network and University of Toronto, Canada.

<sup>3</sup> Department of Biology, Massachusetts Institute of Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

<sup>4</sup> Department of Biological Engineering, Massachusetts Institute of Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

<sup>5</sup> Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215 USA

# These authors contributed equally to this work.

### Summary

In normal cells *p53* is activated by DNA damage checkpoint kinases to simultaneously control the G1/S and G2/M cell cycle checkpoints through transcriptional induction of *p21<sup>cip1</sup>* and *Gadd45 $\alpha$* . In *p53* mutant tumors, cell cycle checkpoints are rewired, leading to dependency on the *p38/MK2* pathway to survive DNA-damaging chemotherapy. Here we show that the RNA binding protein *hnRNPA0* is the “successor” to *p53* for checkpoint control. Like *p53*, *hnRNPA0* is activated by a checkpoint kinase (*MK2*) and simultaneously controls both cell cycle checkpoints through distinct target mRNAs, but unlike *p53* this is through the post-transcriptional stabilization of *p27<sup>Kip1</sup>* and *Gadd45 $\alpha$*  mRNAs. This pathway drives cisplatin resistance in lung cancer demonstrating the importance of post-transcriptional RNA control to chemotherapy response.

<sup>6</sup> corresponding author: myaffe@mit.edu phone: +1 617-452-2103.


#Current address: Molecular Health GmbH, 69115 Heidelberg, Germany

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

#### Author Contributions

Conceptualization, I.G.C. and M.B.Y.; Methodology, I.G.C., S.M., C.J.B., E.R.C., and M.B.Y.; Formal Analysis, I.G.C., C.Q.Z. and M.B.Y.; Investigation, I.G.C., K.A.M., S.M., C.Q.Z., E.R.C., and M.T.H.; Resources, E.R.C., R.A.G., M.S.T., M.T.H., and M.B.Y.; Data Curation, I.G.C. and C.Q.Z.; Writing- Original Draft, I.G.C. and M.B.Y.; Writing- Review and Editing, K.A.M., S.M., C.Q.Z., M.S.T., M.T.H., and M.B.Y.; Visualization, I.G.C. and C.Q.Z.; Supervision, I.G.C., M.T.H., and M.B.Y.; Project Administration, I.G.C. and M.B.Y. Funding Acquisition, I.G.C. and M.B.Y.

## Graphical Abstract



## Introduction

Cytotoxic chemotherapy is a mainstay of cancer treatment, yet the molecular mechanisms that govern sensitivity or resistance to these agents in different tumor types are incompletely understood. Many of the most commonly used chemotherapeutic drugs exert their effects by causing DNA damage, leading to the activation of a complex signaling network that facilitates cell cycle arrest and/or cell death. During tumor evolution, however, many, if not all tumors disrupt components of the DNA damage response network (DDR) to escape oncogene-induced senescence (Bartkova et al., 2006), ultimately contributing to genomic instability. Cytotoxic anti-cancer chemotherapy works in large part by exploiting these DDR differences between normal and tumor cells (Ciccia and Elledge, 2010; Jackson and Bartek, 2009). Some tumor types, such as testicular cancers, show a >80% response rate to chemotherapy (Kelland, 2007). In others, such as non-small cell lung cancer (NSCLC), however, only ~30% of patients respond favorably to cytotoxic platinum-based chemotherapy while the remaining ~70% receive little to no benefit and suffer from drug-related toxicity (Socinski, 2004). Hence, NSCLC is an ideal system to interrogate molecular mechanisms of intrinsic drug resistance. Importantly, the identification of chemotherapy resistance mechanisms could, in principle, both delineate new targets for pharmacological intervention and identify those patients most likely to benefit from specific therapeutic regimens while limiting the extent of toxicity associated with non-selective administration.

Loss or mutation of the tumor suppressor *p53* occurs in approximately 50% of all tumors (Cheek et al., 2011). We recently demonstrated that p53-deficient cells and tumors become dependent on the p38/MK2 pathway for survival in response to topoisomerase inhibitors or platinum-based compounds (Morandell et al., 2013; Reinhardt et al., 2007), two classes of commonly used chemotherapeutic agents. Those observations suggested that pharmacological targeting of MK2, or its downstream effectors, might promote greater clinical efficacy of chemotherapy in p53-deficient tumors (Morandell et al., 2013; Reinhardt et al., 2007). It is also possible that the activity of this pathway could be used to predict the efficacy of chemotherapy. However, measuring MK2 expression levels or activation status as biomarkers of chemotherapy response is likely to be hampered by difficulties in directly

assaying MK2 activity in tumor cells, as well as the presence of high levels of MK2 expression in tumor-infiltrating stromal cells such as macrophages (Morandell et al., 2013). A thorough mechanistic understanding of tumor-specific MK2 effectors, however, could provide novel biomarkers that would facilitate the identification of subsets of patients most likely to benefit from chemotherapy.

We recently found that MK2 post-transcriptionally controls the G2/M checkpoint through the RNA binding protein (RNA-BP) hnRNPA0 promoting Gadd45 $\alpha$  mRNA stabilization and protein production (Reinhardt et al., 2011; 2010). In addition to loss of the G2/M checkpoint, MK2 depleted *p53*-null cells also lose the DNA damage-induced G1/S checkpoint. The molecular mechanism underlying this G1/S checkpoint bypass, the relative contributions of different cell cycle checkpoints to chemotherapy sensitization, and the mechanistic basis for synthetic lethality between the p53 and MK2 pathways in response to DNA damaging chemotherapy have remained elusive.

## Results

### A focused screen implicates p27<sup>Kip1</sup> as an hnRNPA0-dependent G1/S regulator

As shown in Fig 1A, in addition to regulating the G2/M checkpoint, loss of hnRNPA0 results in a pronounced loss of the DNA damage-induced G1/S checkpoint in *p53*-null H1299 NSCLC cells (see also Fig S1A and S1B). Depletion of Gadd45 $\alpha$ , the only known hnRNPA0-target mRNA involved in cell cycle control (Reinhardt et al., 2010), however, failed to recapitulate the effect of hnRNPA0 knockdown on the G1/S checkpoint (Fig 1A, compare orange, blue and green arrows; see also Fig S1A), indicating that hnRNPA0 must regulate the G1/S checkpoint through a different target mRNA(s) (Fig 1B). To identify putative hnRNPA0-target mRNAs that might control the G1/S checkpoint in these *p53*-deficient H1299 cells, we next performed a focused mRNA expression screen following hnRNPA0 depletion, looking for altered regulation of mRNAs whose protein products have been implicated in regulating the G1/S transition in different contexts (Fig 1C). Based on the assumption that hnRNPA0 regulates the stability of its target mRNAs, as has been shown for Gadd45 $\alpha$  (Reinhardt et al., 2010), and thus their mRNA levels, we measured the expression of these G1/S regulators by qRT-PCR in cells depleted of hnRNPA0 by RNAi in the presence or absence of doxorubicin-induced DNA damage. Treatment of H1299 cells with doxorubicin led to a number of changes in the mRNA levels of several G1/S regulators, however only one of these mRNAs, p27<sup>Kip1</sup> appeared to be regulated in an hnRNPA0-dependent manner (Fig 1C). We confirmed this effect of hnRNPA0 on p27<sup>Kip1</sup> mRNA induction using a second independent siRNA targeting a second distinct sequence within hnRNPA0. This independent siRNA efficiently depleted hnRNPA0 at both the mRNA (Fig 1D) and protein level (Fig 1E) and prevented the induction of both p27<sup>Kip1</sup> and Gadd45 $\alpha$  mRNAs in response to DNA damage (Fig 1D). Furthermore the marked induction of p27<sup>Kip1</sup> protein levels that we observed after doxorubicin treatment was blunted by hnRNPA0 knockdown (Fig 1E). Together these data indicate that a single RNA-binding protein, hnRNPA0, regulates the DNA damage-induced G1/S checkpoint independently of stabilizing Gadd45 $\alpha$  and that this G1/S checkpoint may instead be mediated by DNA damage-induced induction of p27<sup>Kip1</sup>.

The most well established mechanism for p27<sup>Kip1</sup> regulation occurs at the level of protein stability through the action of the ubiquitin ligase Skp2 (Frescas and Pagano, 2008). To investigate whether increased protein stability could account for the up-regulation of p27<sup>Kip1</sup> protein after DNA damage (Fig 1E) we measured p27<sup>Kip1</sup> protein half-life after doxorubicin-induced DNA damage by blocking translation with cycloheximide (Fig 1F and Fig S1B). Surprisingly, despite a two- to threefold increase in total p27<sup>Kip1</sup> protein levels (Fig 1E), doxorubicin treatment led to a slight decrease in p27<sup>Kip1</sup> protein stability (Fig 1F and S1B), indicating that the observed induction of p27<sup>Kip1</sup> following DNA damage does not result from increased protein stability. Since hnRNPA0 is known to regulate Gadd45 $\alpha$  in a DNA damage-dependent manner through stabilization of its mRNA (Reinhardt et al., 2010), we hypothesized that the increased p27<sup>Kip1</sup> levels seen after DNA damage could be due to a similar stabilization of p27<sup>Kip1</sup> mRNA. To test this, we treated H1299 cells with doxorubicin for 16 hr, then added actinomycin D to the culture medium to prevent new transcription and measured p27<sup>Kip1</sup> mRNA decay by qRT-PCR. Doxorubicin treatment led to a fourfold increase in the half-life of p27<sup>Kip1</sup> mRNA (Fig 1G), similar in magnitude to the observed increase in total p27<sup>Kip1</sup> mRNA levels (Fig 1C and 1D). Next, we set out to examine whether the regulation of p27<sup>Kip1</sup> by hnRNPA0 is mediated by direct binding. *In vitro* binding experiments with a fragment of the p27<sup>Kip1</sup> 3' UTR harboring putative hnRNPA0 binding sites (Fig S1C) (Wang et al., 2013) and the purified recombinant hnRNPA0 RNA recognition motifs (RRMs) (Fig S1D and S1E) suggest that hnRNPA0 protein binds directly to the p27<sup>Kip1</sup> mRNA via the 3' UTR. Taken together, these observations suggest that the observed up-regulation of p27<sup>Kip1</sup> in response to DNA damage occurs primarily at the post-transcriptional level through increased mRNA stability mediated by hnRNPA0.

### **p27<sup>Kip1</sup> controls the DNA damage-induced G1/S checkpoint in p53-deficient cells**

p27<sup>Kip1</sup> is a prototypical CDK inhibitor that binds and inhibits Cyclin A and E/CDK2 and Cyclin D/CDK4 complexes to promote G1 arrest during entry into quiescence (Toyoshima and Hunter, 1994). However a role for p27<sup>Kip1</sup> in the establishment of the G1 checkpoint in response to DNA damage has not been well described. This potential role for p27<sup>Kip1</sup> as a DNA damage-induced G1/S checkpoint regulator would likely be particularly important in cells with defects or mutations in the p53 pathway since those cells lack the p21(Cip1)-dependent G1/S checkpoint (see Fig 4E), and p27<sup>Kip1</sup> and p21 perform largely overlapping functions. To test whether this MK2/hnRNPA0/p27<sup>Kip1</sup> pathway that we have characterized was causally responsible for loss of the G1/S checkpoint in p53-null MK2/hnRNPA0 depleted cells, we knocked down p27<sup>Kip1</sup> using RNAi (Fig 2A) and monitored the integrity of the G1/S checkpoint by flow cytometry. In control RNAi-treated cells, a substantial fraction of the population (~15-20%) remains arrested in G1 (Fig 2B, top right panel and S2A top middle panel) 16 hr after doxorubicin treatment, but this G1 arrest was almost completely ablated upon p27<sup>Kip1</sup> knockdown (Fig 2B, bottom right panel and S2A bottom middle panel). Quantification from three independent experiments revealed a near complete loss of G1 cells in the p27<sup>Kip1</sup> knockdown condition (Fig 2C). We confirmed that the loss of the G1 population in p27<sup>Kip1</sup> depleted cells was due to inappropriate progression through the cell cycle, rather than G1-driven cell death, using EdU (5-ethynyl-2'-deoxyuridine) labeling, a thymidine analog that is incorporated into DNA during active synthesis in S-phase (Buck et al., 2008) (Fig 2D). As shown in Fig 2E, DNA damage induced by 1  $\mu$ M doxorubicin

resulted in a 90% decrease in EdU incorporation when assayed within the 1 hour window between 15 and 16 hr after treatment, relative to undamaged control cells (Fig 2E, black bars; see also Fig S2C) due to implementation of G1/S and intra-S phase checkpoints. However, depletion of p27<sup>Kip1</sup> with either an siRNA or an shRNA targeting distinct sequences in the p27<sup>Kip1</sup> mRNA, resulted in a greater than 2-fold increase in EdU incorporation at this timepoint after damage, (Fig 2E, red bars; see also Fig S2C) suggesting that p27<sup>Kip1</sup> depleted cells had indeed entered into S-phase due to loss of the G1/S checkpoint (Fig 2B). Importantly, depletion of p27<sup>Kip1</sup> had no significant effect on EdU incorporation in the absence of DNA damage (Fig S2B). Furthermore, the magnitude of enhanced EdU incorporation following p27<sup>Kip1</sup> knockdown mirrored that seen with hnRNPA0 knockdown (Fig 2E, white bars see also Fig S2C) indicating that p27<sup>Kip1</sup> is the major hnRNPA0-target mRNA controlling the G1/S checkpoint.

### **MK2-mediated phosphorylation of hnRNPA0 in response to DNA damage induces binding to its target RNAs**

Since MK2 is an important upstream regulator of hnRNPA0 function through phosphorylation of a single residue, serine 84 (Fig 3A) (Reinhardt et al., 2010; Rousseau et al., 2002), we next examined the role of MK2 on induction of p27<sup>Kip1</sup> mRNA. As shown in Figure 3B and 3C, depletion of MK2 by RNAi prevented both the DNA damage-induced phosphorylation of serine 84 of hnRNPA0 (Fig 3B) and completely ablated p27<sup>Kip1</sup> mRNA induction following doxorubicin treatment (Fig 3C). This finding that p27<sup>Kip1</sup> mRNA is induced in an MK2 and hnRNPA0-dependent manner suggests a direct interaction between hnRNPA0 protein and p27<sup>Kip1</sup> mRNA (Fig S1D-E) that can be modulated by phosphorylation of hnRNPA0 by MK2. To test this, we performed an RNA immunoprecipitation experiment using H1299 cell lines stably expressing HA-tagged WT hnRNPA0 (HA-hnRNPA0-WT), or a mutant version in which the MK2 phosphorylation site was mutated to an alanine (HA-hnRNPA0-S84A). As shown in Fig 3D, doxorubicin-induced DNA damage led to an eightfold increase in the association of p27<sup>Kip1</sup> mRNA with HA-hnRNPA0-WT and a fourteen fold increase in the association of Gadd45 $\alpha$  mRNA (Fig 3D). In contrast, mutation of the MK2 phosphorylation site in hnRNPA0 (Fig 3D, right-most bars) completely eliminated these DNA-damage induced associations. Together with the previous *in vitro* binding experiments (Fig S1D and S1E), these data indicate that p27<sup>Kip1</sup> mRNA is stabilized in response to DNA damage through a direct interaction with hnRNPA0 in an MK2-regulated manner.

### **MK2 phosphorylation of hnRNPA0 promotes its cytoplasmic accumulation in response to DNA damage**

MK2 phosphorylation of serine 84 of hnRNPA0 is clearly important for its interaction with its target mRNAs p27<sup>Kip1</sup> and Gadd45 $\alpha$  (Fig 3D) (Reinhardt et al., 2010) but the molecular basis has remained elusive. Other members of the hnRNP family of RNA binding proteins shuttle between the nucleus and the cytoplasm under steady state conditions, but in response to certain extracellular stimuli they can be preferentially retained in one of the two sub-cellular compartments (Shyu and Wilkinson, 2000). To determine whether hnRNPA0 sub-cellular localization was altered by DNA damage, we subjected H1299 cell lines that stably expressing HA-hnRNPA0-WT or HA-hnRNPA0-S84A, to doxorubicin treatment, and



examined their localization by subcellular fractionation and by immunofluorescence microscopy of intact cells. In undamaged cells, hnRNPA0 was predominantly nuclear, as assessed by western blotting of fractionated lysates for the HA-tagged protein, lamin A (a nuclear marker) and  $\gamma$ -tubulin (a cytoplasmic marker) (Fig 3E compare lanes 1 and 3). This was further confirmed by immunofluorescence in whole cells using antibodies against the HA tag (Fig 3F, top row). Doxorubicin-induced DNA damage led to a decrease in the nuclear fraction of hnRNPA0 (Fig 3E, compare lanes 1 and 2) with a concomitant increase in its cytoplasmic abundance (Fig 3E, compare lanes 3 and 4). This was further substantiated by whole cell imaging (Fig 3F 2<sup>nd</sup> row, and Fig 3G), indicating that DNA damage induces the cytoplasmic relocation of hnRNPA0. Strikingly, the non-phosphorylatable HA-hnRNPA0-S84A mutant displayed a similar nuclear-cytoplasmic distribution to HA-hnRNPA0-WT in the basal undamaged state (Fig 3E, lanes 5 and 7), but its localization was entirely unaltered by doxorubicin treatment (Fig 3E, compare lanes 5 and 6; Fig 3F, rows 3 and 4, and Fig 3G). Quantification of the imaging data from multiple experiments revealed a ~30% increase in cells with predominantly cytoplasmic HA-hnRNPA0-WT upon doxorubicin treatment that was not observed in the cells expressing the HA-hnRNPA0-S84A phospho-defective form (Fig 3G). Taken together, these biochemical and image-based data indicate that MK2-mediated phosphorylation of hnRNPA0 leads to an increase in its cytoplasmic localization in response to DNA damage where it is well positioned to bind to and stabilize its target mRNAs p27<sup>Kip1</sup> and Gadd45 $\alpha$ .

### Synthetic lethality between hnRNPA0-loss and a defective p53 pathway in response to chemotherapy

Since loss of hnRNPA0 abrogates both the G1 checkpoint through p27<sup>Kip1</sup> (Fig 1 and 2) and the G2/M checkpoint through Gadd45 $\alpha$  (Reinhardt et al., 2010), thereby reducing the time for DNA repair prior to the next cell cycle transition, we hypothesized that hnRNPA0-depleted cells would be sensitized to killing by DNA damaging chemotherapy. To test this, cell death was assayed by measuring cleaved caspase 3 in control or hnRNPA0-depleted H1299 cells in response to doxorubicin-induced DNA damage. As shown in Figure 4A, knockdown of hnRNPA0 in human *p53*-deficient/null H1299 cells resulted in two-fold more cell death in response to low-dose doxorubicin as compared to control RNAi-treated cells (Fig 4A, black vs white +Dox bars). The effect of hnRNPA0 depletion on cisplatin-induced cell killing was even more pronounced, resulting in a fourfold increase in death compared to the control vehicle-treated cells (Fig 4B; black vs white +Cis bars). Furthermore, we could recapitulate these findings from human NSCLC cells with two independent shRNAs in a genetically defined murine cell line KP7B (Fig 4C and S4A) (Doles et al., 2010) derived from a *K-Ras*<sup>G12D</sup>;*p53*<sup>-/-</sup> NSCLC tumor model (Jackson, 2005). We further confirmed that our acute measure of cell death in response to DNA damaging chemotherapy reflected long-term survival of these cells using both colony formation assays (Fig S4B) and fluorescence-labeling based competition assays (Fig S4C and S4D). These data indicate that loss of hnRNPA0 sensitizes *p53*-null cells to the cytotoxic effects of chemotherapy.

Many human tumors are not entirely *p53*-deficient (i.e. null), but instead have point mutations in critical “hotspot” regions of this prominent tumor suppressor. To determine whether *p53* status was an important biomarker of chemo-sensitization mediated by

hnRNPA0 loss, we knocked down hnRNPA0 by RNAi in a panel of *p53*-mutant and *p53*-WT NSCLC cell lines, treated them with cisplatin, and assayed cell death (Fig 4D and S4F-H). As shown in Figure 4D hnRNPA0 knockdown enhanced cisplatin-induced cell death in all *p53*-mutant cell lines to varying degrees, with H2009 and H1734 cells being the most responsive (Fig 4D first two bars). Both of these cell lines express a homozygous *p53*<sup>R273L</sup> mutant protein, the most common *p53* mutation found in NSCLC, accounting for >5% of all *p53* mutations ([http://p53.free.fr/Database/p53\\_cancer/p53\\_Lung.html](http://p53.free.fr/Database/p53_cancer/p53_Lung.html)). Analysis of *p53* target gene expression by qRT-PCR confirmed a largely abrogated *p53* response in the *p53*-mutant cell lines (Fig 4E). *P53* mutations that functionally disable the WT protein often lead to stabilization of *p53* proteins due to loss of a *p53*-driven MDM2-mediated negative feedback (Olive et al., 2004). Indeed our *p53*-mutant cell lines were characterized by high basal levels of *p53* that were not further stabilized upon DNA damage (Fig 4E), in marked contrast to the WT cell lines that expressed low basal levels of *p53* that was substantially induced upon DNA damage (Fig 4E). Since not all *p53* mutations disable *p53* function equivalently, it has been proposed that higher *p53* protein expression can be used as a surrogate marker for more disabling *p53* mutations (Morandell et al., 2013; Reinhardt et al., 2007; Tsao et al., 2007; Yemelyanova et al., 2011). Interestingly, we observed that basal *p53* levels (as measured in Fig 4E) were highly correlated with the extent to which hnRNPA0-loss induced chemo-sensitization in our cell line panel (Fig 4F,  $R^2 = 0.8903$ ,  $p = 0.016$ ), suggesting that *p53* expression might serve as a generalizable biomarker for the extent to which cells are dependent upon the hnRNPA0 pathway for survival following treatment with DNA damaging chemotherapy.

Clearly both *p53*-null and mutant cells are sensitized to DNA damaging chemotherapy while *p53* WT cells appear be unaffected by hnRNPA0 loss. To distinguish whether this synthetic lethal interaction between *p53* loss of function and hnRNPA0 depletion was due to chronic adaptive changes in cells with abrogated *p53* responses, or an acute effect of *p53* loss of function, we then performed combination hnRNPA0/*p53* knockdown experiments in *p53* WT H1944 cells (Fig 4G). Depletion of hnRNPA0 alone had no demonstrable effect on cisplatin-induced cell death in this *p53*-proficient cell line (Fig 4G, compare 2<sup>nd</sup> and 4<sup>th</sup> white bars). As expected, *p53* knockdown completely abrogated cisplatin-induced cell death (Fig 4G, compare 2<sup>nd</sup> white bar and 2<sup>nd</sup> blue bar). Strikingly, combined knockdown of hnRNPA0 on a background of *p53* depletion re-sensitized these cells to cisplatin-induced cell death (Fig 4G, compare 2<sup>nd</sup> and 4<sup>th</sup> blue bars and Fig S4H). Similar results were obtained with Doxorubicin treatment in A549 cells, a second *p53* WT cell line, upon single and combined hnRNPA0/*p53* knock-down (Fig S4I). These data suggest that targeting of hnRNPA0 can sensitize cells that have acutely lost *p53* function to DNA damaging chemotherapy.

To address the importance of MK2 phosphorylation of hnRNPA0 in mediating cisplatin resistance, we performed knockdown-rescue experiments with WT and mutant hnRNPA0 in KP7B cells (Fig S4J). Endogenous hnRNPA0 was knocked-down with a retroviral shRNA targeting the 3' UTR followed by reconstitution with either HA-hnRNPA0-WT or HA-hnRNPA0-S84A cDNA of human origin (Fig S4J, upper panel, note mobility shift due to the 2X HA-tag). These cells were then treated with cisplatin and assayed for cell death (Fig S4J, middle panel). Knockdown of hnRNPA0 increased cell death in response to cisplatin (Fig



S4J, bottom panel, compare 2<sup>nd</sup> black bar and 2<sup>nd</sup> white bar) while re-expression of HA-hnRNPA0-WT completely abrogated this effect (Fig S4J, bottom panel, compare 2<sup>nd</sup> white bar to 4<sup>th</sup> white bar). In stark contrast, re-expression of HA-hnRNPA0-S84A failed to rescue the hnRNPA0 knockdown phenotype (Fig S4J, bottom panel, compare 2<sup>nd</sup> white bar and 6<sup>th</sup> white bar). These data suggest that phosphorylation of hnRNPA0 is not only required for its interaction with target mRNAs, but also required for cells to resist killing by chemotherapy, potentially due to a requirement for damage-induced hnRNPA0 cytoplasmic localization (Fig 3).

### Reduced hnRNPA0 activity promotes cisplatin efficacy *in vivo* in a murine p53-deficient NSCLC model

To determine whether hnRNPA0 promotes resistance of established lung tumors to cisplatin-based chemotherapy *in vivo* we took advantage of a transplantable model of NSCLC (Doles et al., 2010; Morandell et al., 2013). In this model, KP7B cells are transplanted in syngeneic, immune-competent recipient mice (Fig 5A) (Doles et al., 2010). The advantages of this model over a traditional xenograft approach are threefold: First, tumors arising in recipient mice are pathologically and molecularly indistinguishable from the tumors from which they were derived (Doles et al., 2010), which are themselves strikingly similar to their human counterparts (Jackson, 2005; Sweet-Cordero et al., 2004). Second, the cells give rise to tumors in the correct anatomical location in the presence of a fully functional host immune system. Lastly, and most importantly for our studies, this model is highly tractable and allows genetic manipulation of proteins of interest prior to transplantation.

We generated stable KP7B cell lines by introduction of an hnRNPA0-specific shRNA that efficiently knocked down its intended target (Fig S5A), along with a retrovirus expressing luciferase to facilitate imaging of response to therapy (Fig 5A). These cell lines were then transplanted into multiple syngeneic recipient mice, and tumors were allowed to form until strong bioluminescence was observed in the lungs of all animals (16 days post-transplantation) in order to assess therapeutic response in established tumors. While no significant difference in bioluminescence was observed between control and hnRNPA0-depleted tumors in the absence of DNA damaging chemotherapy (Fig 5B-C and Fig S5B, pre-treatment condition), upon treatment with cisplatin, control tumors continued to grow rapidly but growth of hnRNPA0-depleted tumors was markedly suppressed (Fig 5B-C). MicroCT imaging of a second cohort of animals treated with a single high dose of cisplatin (10 mg/Kg) confirmed the superior response of hnRNPA0-depleted tumors to chemotherapy (Fig S5B and S5C-D). Consistent with the short term tumor response data, mice transplanted with hnRNPA0-proficient cells obtained no significant survival benefit from cisplatin treatment (Fig 5D, compare red and blue lines,  $p=0.52$ ) indicating that tumors in this model are entirely recalcitrant to cisplatin-based chemotherapy (Doles et al., 2010). In contrast, animals transplanted with hnRNPA0-depleted tumors displayed a significant survival benefit upon cisplatin treatment (Fig 5E, compare red and blue lines,  $p<0.0001$ ) indicating that the acute tumor growth effect we observed in response to therapy (Fig 5B-C) directly translated into an extension of lifespan in this murine NSCLC model (Fig 5D-E). Taken together, these data indicate that the presence of hnRNPA0 promotes resistance of established lung tumors to cisplatin-based chemotherapy *in vivo*.

### hnRNPA0 promotes resistance to chemotherapy through stabilization of p27<sup>Kip1</sup> and Gadd45 $\alpha$ mRNAs

Our data demonstrate that in response to DNA damaging chemotherapy, MK2-mediated phosphorylation of hnRNPA0 stabilizes the mRNAs of p27<sup>Kip1</sup> and Gadd45 $\alpha$  to control the G1/S and G2/M checkpoints, respectively (Fig 6A). However, the relative contributions provided by either of these two target mRNAs to the overall enhanced chemo-sensitivity of hnRNPA0 knockdown cells/tumors (Fig 4-5) is unknown. To determine this, we depleted *p53*-null H1299 cells of either p27<sup>Kip1</sup> alone, Gadd45 $\alpha$  alone, or both RNAs simultaneously. The isolated or combined knockdown of p27<sup>Kip1</sup> and Gadd45 $\alpha$  had no significant effect on untreated cells, indicating that loss of these two proteins is not acutely toxic to cells in the absence of DNA damage (Fig 6B and S6A-B). Knockdown of either of these hnRNPA0-target mRNAs individually had no effect on cell death in response to cisplatin (Fig 6B, red and blue bars compared to the black bars) or doxorubicin (Fig S6B). Strikingly, however, co-depletion of both hnRNPA0-target mRNAs resulted in a markedly enhanced amount of cell death, and fully recapitulated the effect of hnRNPA0 knockdown on response to cisplatin (Fig 6B, compare white bars and purple bars) and doxorubicin (Fig S6B). Taken together, these data indicate that MK2/hnRNPA0 promotes the resistance of *p53*-defective cells to chemotherapy by the combined action of stabilizing both p27<sup>Kip1</sup> and Gadd45 $\alpha$  mRNAs to control the G1/S and G2/M checkpoints, respectively.

### Reduced levels of hnRNPA0-target mRNAs correlate with favorable response to adjuvant chemotherapy in human NSCLC patients

The observation that the MK2/hnRNPA0 pathway promotes resistance to chemotherapy in NSCLC models through the coordinate post-transcriptional control of the p27<sup>Kip1</sup> and Gadd45 $\alpha$  regulated DNA damage G1/S and G2/M checkpoints suggests that human tumors with low levels of activity through this pathway, either by means of natural heterogeneity or pharmacological intervention, might be more likely to respond to cisplatin-based chemotherapy. To test this, we made use of data from the NCIC CTG JBR10 clinical trial in which stage 1B and 2 NSCLC patients had their tumors surgically resected and were then either observed or given cisplatin/vinorelbine adjuvant chemotherapy (Winton et al., 2005). This dataset was selected for analysis for several reasons. First, banked snap-frozen tumors from a subset of patients were subjected to gene expression profiling prior to therapy, thus facilitating identification of genetic determinants of therapeutic response (Zhu et al., 2010). Second, this trial had a control/observation arm thus allowing for factors that regulate response to therapy (predictive markers) to be differentiated from those that affect tumor growth *per se* (prognostic markers). Unsupervised clustering on p27<sup>Kip1</sup> and Gadd45 $\alpha$  expressions was used as a surrogate for assessing activity through the MK2/hnRNPA0 pathway and two distinctive clusters were identified (Fig S6C); one cluster with high expression of p27<sup>Kip1</sup> and Gadd45 $\alpha$  and the other with low expression. We focused our analysis on stage 2 patients (Table 1) as adjuvant chemotherapy has been shown to be beneficial mainly in this subset of early stage patients (Winton et al., 2005). As shown in Figure 6C, patients with high expression of p27<sup>Kip1</sup> and Gadd45 $\alpha$  did not benefit from adjuvant chemotherapy (Fig 6C, compare orange and green lines, HR 1.48, 95%CI 0.47-4.67,  $p=0.502$ ). Whereas, patients with low levels of these hnRNPA0-target mRNAs received significant benefit from adjuvant chemotherapy (Fig 6D, compare orange and green

lines, HR 0.23 95%CI 0.07-0.71  $p=0.011$ ). Importantly, patients in the observation arm of the trial whose tumors express low levels of p27<sup>Kip1</sup> and Gadd45 $\alpha$  appeared to show the poorest survival of all groups analyzed (Fig 6D, orange line) similar to mice harboring hnRNPA0-depleted tumors (Fig 5D and 5E, compare blue line in 5D to the blue line in 5E,  $p=0.0023$ ). Moreover, only consideration of both p27<sup>Kip1</sup> and Gadd45 $\alpha$  expression together, but neither alone, had a significant association with therapeutic response (Fig S6D). Since our data from a panel of NSCLC cell lines indicated that high basal p53 protein levels correlated with superior response to hnRNPA0 knockdown-induced chemo-sensitization (Fig 4D-F), we further stratified patients based upon p53 immuno-histochemistry status: p53 IHC positive/putatively mutant and p53 IHC negative/putatively WT (Tsao et al., 2007). While the number of patients is very small, the data suggests that patients whose tumors express low levels of p27<sup>Kip1</sup> and Gadd45 $\alpha$ , and additionally have stabilizing *p53* mutations, benefit most from adjuvant cisplatin-based chemotherapy (Fig S6E-F). Taken together, these murine (Fig 5) and human clinical data (Fig 6 and S6) indicate that hnRNPA0 promotes resistance to chemotherapy in *p53*-mutant NSCLC through p27<sup>Kip1</sup> and Gadd45 $\alpha$  (Fig 6A).

### **Mutual exclusivity of the p53 and MK2/hnRNPA0 pathways is ensured by p53/p21-mediated suppression of hnRNPA0**

To ascertain the molecular basis for the *p53* context-dependence of hnRNPA0 for DNA damage tolerance, we next investigated whether there is a regulatory relationship between p53 and hnRNPA0. We noted that when p53 proficient cells were treated with doxorubicin, a marked suppression of hnRNPA0 protein levels was observed (Fig 7A, compare lanes 1 and 2 and first two black bars), that was not seen in *p53*-null cells (see Fig 1E). To examine whether this reduction in hnRNPA0 required p53, we knocked-down p53 with siRNA, treated the cells with doxorubicin, and measured hnRNPA0 protein levels. The pronounced decrease in hnRNPA0 following DNA damage that we observed previously was largely ablated upon p53 knockdown (Fig 7A) suggesting that p53 or its downstream effectors actively suppresses hnRNPA0. Conversely, activation of p53 even in the absence of DNA damage was sufficient to suppress hnRNPA0. In these experiments treatment of A549 cells with the MDM2 inhibitor Nutlin 3a to upregulate p53 resulted in down-regulation of hnRNPA0 protein and mRNA in control siRNA transfected cells (Fig 7B, left and right lower panels, black bars), but not in p53-depleted cells (Fig 7B, red bars). These findings suggest that the drop in hnRNPA0 protein levels is likely a consequence of decreased mRNA levels, either due to decreased transcription, or to post-transcriptional destabilization of the hnRNPA0 mRNA.

Since many RNA binding proteins are auto-regulated or regulated by other RNA-BPs at the post-transcriptional level, and the hnRNPA0 3' UTR is long and highly conserved (Fig S7A) we first examined whether hnRNPA0 mRNA was destabilized upon p53 activation. To test this we measured hnRNPA0 mRNA stability in Nutlin 3a-treated cells in the same manner as we had assessed p27<sup>Kip1</sup> stability in response to doxorubicin (Fig 1G). As shown in Figure 7C, the half-life of hnRNPA0 mRNA dropped from ~16 hr in vehicle treated cells to ~6 hr following p53 activation with Nutlin 3a. Moreover, half-life estimates averaged from multiple experiments revealed a ~50% decrease in hnRNPA0 mRNA half-life upon p53 activation (Fig 7D), closely mirroring the drop seen in total hnRNPA0 mRNA levels (Fig

7B, right panel, black bars). Since p21 is the primary effector of p53-mediated G1/S checkpoint control, we next asked whether suppression of the hnRNPA0 successor pathway was p21-dependent. We knocked down p21 using siRNA in A549 cells, treated them with Nutlin 3a to activate p53 (Fig 7E, left panel) and measured hnRNPA0 protein and mRNA levels. Indeed, the repression of hnRNPA0 mRNA (Fig 7E, right panel) and hnRNPA0 protein (Fig S7B) was largely ablated by depletion of p21. While the precise molecular basis for this p21-dependent hnRNPA0 mRNA destabilization remains to be determined, these findings clearly point to an important role for p21 induction in suppression of hnRNPA0 expression. These data suggest that rather than functioning in parallel pathways, the primary p53/p21 and the successor MK2/hnRNPA0 pathways of cell cycle checkpoint control are mutually exclusive, and that this is ensured by suppression of the successor pathway at the level of hnRNPA0 mRNA destabilization (Fig 7F).

## Discussion

Post-transcriptional control of gene expression is becoming increasingly appreciated as a target of the DNA damage response (DDR). Several unbiased screens have implicated RNA binding proteins (RNA-BPs) as one of the most enriched classes of genes involved in activating and modulating the DDR (Beli et al., 2012; Matsuoka et al., 2007; Paulsen et al., 2009; Reinhardt et al., 2010). To date, however, there are few examples of RNA-BPs that have been implicated as functionally important in the execution of specific cellular decisions in response to DNA damage, or had their relevant target RNAs interrogated in this regard (Abdelmohsen et al., 2007). Here we have shown that the RNA-BP hnRNPA0 is a major substrate of the checkpoint kinase MK2, and that it enforces cell cycle arrest and promotes resistance to DNA damaging chemotherapy through two distinct target mRNAs that respectively control the G1/S and G2/M DNA damage checkpoints in cultured cells and *in vivo*. These findings indicate that in addition to modulating the DDR itself, RNA-BPs are intimately involved in critical life and death decisions. More broadly, recent advances in the high-throughput identification of RNA-protein interactions, such as **High Throughput Sequencing CrossLink Immuno-Precipitation (HITS-CLIP)** (Darnell, 2010), should help to elucidate the role of other RNA-BPs identified in recent screening approaches and may shed light on the breadth and extent of post-transcriptional control of gene expression in the context of the DDR.

Our work demonstrates that hnRNPA0 regulates p27<sup>kip1</sup> expression in a context-specific manner in response to DNA damaging chemotherapy and complements a growing body of literature documenting the critical contribution of post-transcriptional control by multiple regulators (e.g. miR-221, DND1 and Pumilio) to p27<sup>kip1</sup> expression (Kedde et al., 2007; 2010). The binding of hnRNPA0 to p27<sup>kip1</sup> mRNA appears to occur via the 3' UTR but in a region that is distinct from that of miR-221, DND1 or Pumilio (Kedde et al., 2007; 2010). Together these data indicate that the p27<sup>kip1</sup> 3' UTR acts as a platform for different post-transcriptional regulators dependent upon the extra-cellular cues (e.g. growth factors, DNA damage etc) and genetic context (e.g. p53 mutation) in which a specific cell exists.

MK2 activation of cell cycle checkpoints in *p53*-compromised cells promotes resistance to doxorubicin or cisplatin-based chemotherapy, raising the possibility that targeting this

pathway in human tumors may preferentially kill *p53*-mutant tumor cells while sparing *p53*-WT normal cells (Morandell et al., 2013; Reinhardt et al., 2007). MK2 controls the G2/M checkpoint by regulating the activity of the RNA-BP hnRNPA0 and causing stabilization of Gadd45 $\alpha$  mRNA (Reinhardt et al., 2010). Here we have shown that, in addition to regulation of the G2/M checkpoint, hnRNPA0 also enforces a G1/S checkpoint through stabilization of p27<sup>Kip1</sup> mRNA. Traditionally p27<sup>Kip1</sup> is regarded as the major CDK inhibitor that induces G1 arrest upon contact inhibition or during terminal differentiation (Hsieh et al., 2000; Polyak et al., 1994) but a role for p27<sup>Kip1</sup> in control of the DNA damage checkpoints has largely been overlooked with two notable exceptions (Cuadrado et al., 2009; Lontos et al., 2010). Our data clearly implicate p27<sup>Kip1</sup> as the major controller of the G1/S checkpoint following DNA damage in *p53*-null cells. Interestingly, a previous report implicated p27<sup>Kip1</sup> in long-term maintenance of cell cycle arrest in *p53*-WT A549 cells after long-term exposure to doxorubicin (Cuadrado et al., 2009). In that study p27<sup>Kip1</sup> was only important for controlling the G1/S checkpoint once the initial wave of p53-p21 activity had diminished (Cuadrado et al., 2009). In agreement with these observations, we show that in those same *p53*-WT A549 cells acute (24 hr) activation of p53 by doxorubicin or MDM2 inhibition suffices to down regulate hnRNPA0 in a p53/p21-dependent manner. These data support a mutual exclusivity model where p27<sup>Kip1</sup> control of the G1/S checkpoint only becomes essential in cells that do not have an active p53-p21 pathway and thus fail to suppress hnRNPA0 (Fig 7F). Interestingly, Gadd45 $\alpha$  is a transcriptional target of p53 in response to DNA damage, but in *p53*-null cells is induced by the MK2/hnRNPA0-dependent stabilization of its mRNA. Therefore, Gadd45 $\alpha$  control of the G2/M checkpoint is functionally maintained in the absence of p53 by a switch from transcriptional to post-transcriptional control (Fig 7F). Together these data indicate that hnRNPA0 is the “successor” to p53 for checkpoint control in response to DNA damaging chemotherapy and that a mechanistic switch from transcriptional control of p21 and Gadd45 $\alpha$  to post-transcriptional control of p27<sup>Kip1</sup> and Gadd45 $\alpha$  enforces the G1/S and G2/M checkpoints and drives chemo-resistance (Fig 7F).

Intrinsic drug resistance is a major obstacle to the successful treatment of human malignancies. Some patients receive significant benefit from cytotoxic DNA-damaging chemotherapy but identifying these patients *a priori* is a significant challenge (Kelland, 2007). Here, we have shown that *p53*-null/mutant NSCLCs rely on an MK2/hnRNPA0/p27<sup>Kip1</sup>/Gadd45 $\alpha$  pathway to promote cell cycle arrest and resist killing by chemotherapy. In light of our findings in tumor cell lines and animal models, we investigated whether the status of this pathway correlated with therapeutic response in NSCLC patients. Consistent with our experimental data, we observed that stage 2 NSCLC patients with low levels of hnRNPA0-target mRNAs received significant benefit from adjuvant chemotherapy after surgical resection that was exacerbated still further when analyzing patients with *p53*-mutant tumors, while those with high levels of MK2/hnRNPA0-target mRNAs did not. While our findings in this well-annotated small patient cohort will require independent large scale verification, our data suggests that the use of p27<sup>Kip1</sup> and Gadd45 $\alpha$  mRNA levels in combination with p53 IHC as predictive “biomarkers” could identify a subset of patients at diagnosis that are most likely to benefit from platinum-based chemotherapy. Our data therefore highlight a critically important unifying role for the cytoplasmic MK2/hnRNPA0



p53-successor pathway in dictating tumor response to therapy in NSCLC through post-transcriptional control of two distinct cell cycle checkpoints (Fig 7F).

## Experimental Procedures

### RNA-IP and qRT-PCR

RNA-IPs were performed as described previously (Reinhardt et al., 2010) with the addition of 4-thiouridine (4SU) labeling prior to drug treatment. Briefly, H1299 cells expressing HA-hnRNPA0 were treated with 100 mM 4SU for 24 hr, followed by treatment with 2  $\mu$ M doxorubicin for 16 hr. At the end of doxorubicin treatment cells were washed once in ice-cold PBS and crosslinked at 365 nm as described (Hafner et al., 2010). Cells were then scraped in ice-cold PBS and RNA-IP performed as described previously (Keene et al., 2006; Reinhardt et al., 2010) using HA-agarose beads (Sigma-Aldrich). For qRT-PCR analysis RNA was extracted using TRIzol reagent (Ambion) according to the manufacturer's instructions and 1  $\mu$ g of total RNA was used for reverse transcription using the superscript III first-strand synthesis kit (Invitrogen) and oligo-dT priming as per the manufacturer's instructions. For qPCR cDNA was amplified using SYBR green PCR mastermix (Applied Biosystems) according to the manufacturer's cycling conditions for 40 cycles on a Bio-Rad C1000 Thermal Cycler. Data were analyzed using the delta-delta Ct method as described previously (Cannell et al., 2010) and plotted as fold change versus control.

### Murine NSCLC transplant model

50,000 KP7B cells, labeled with GFP-Luciferase, were transplanted into 10-12 week old syngeneic C57BL6/Jx129-JAE male recipient mice 6 hr after 5 Gy whole body irradiation as described previously (Doles et al., 2010). Tumors were allowed to form for approx. 2 weeks and tumor growth was measured by microCT imaging on a eXplore CT120-whole mouse MicroCT (GE Healthcare) (45- m resolution, 80 kV, with 450- A current) as described previously (Doles et al., 2010) or bio-luminescent imaging on a IVIS Spectrum-bioluminescent and fluorescent imaging system (Xenogen Corporation). For all imaging procedures animals were pre-anesthetized with isoflourane. For drug treatments, cisplatin was dissolved in saline and injected IP at 10 mg/kg for single high dose treatment, or with 7 mg/kg once weekly for a total of three weeks for low dose treatment. Mice were sacrificed when moribund or when they had lost 20% of their initial body weight, whichever occurred sooner, according to MIT Committee on Animal Care guidelines. All mouse studies were approved by the MIT Institutional Committee for Animal Care (CAC), and conducted in compliance with the Animal Welfare Act Regulations and other federal statutes relating to animals and experiments involving animals and adheres to the principles set forth in the Guide for the Care and Use of Laboratory Animals, National Research Council, 1996 (Institutional Animal Welfare Assurance no. A-3125-01).

### Retrospective analysis of p27<sup>Kip1</sup> and Gadd45 $\alpha$ mRNA expression and therapeutic response in NSCLC

This study used human tissues from a snap-frozen lung tumor bank that was established at the Princess Margaret Hospital and Toronto General Hospital in 1996, after approval by the Research Ethics Board of the University Health Network. Patients, demographic and clinical



follow-up information was also obtained after Research Ethics Board approval for chart reviews. Expression of p27<sup>Kip1</sup> and Gadd45 $\alpha$  mRNAs in 133 non-small cell lung cancer samples profiled by using Affymetrix U133A (Zhu et al., 2010) represented by probe set 209112\_at and 203725\_at, respectively. Two clusters were identified based on the expressions of p27<sup>Kip1</sup> and Gadd45 $\alpha$  using hierarchical clustering (Sturn et al., 2002). The 2 clusters were defined as low and high expressed groups based on the expression of these two genes (Fig S6C). For survival analysis, lung cancer specific survival was used as the survival endpoint and Cox proportional hazards regression (SAS v9.3, SAS Institute Inc, Cary) was used to estimate the hazard ratio and test the significance. A p value of less than 0.05 was considered as significant. Immunohistochemistry (IHC) staining and scoring for p53 protein on tissue microarray (TMA) was described in detail in (Tsao et al., 2007). Briefly, 4 $\mu$ m sections from TMA were mounted onto slides. DO7 antibody for p53 (NovoCastra Laboratories, Newcastle upon Tyne, United Kingdom) was diluted at 1:200 and applied to the sample which were microwave heated for antigen retrieval. The dilution was optimized *a priori* to ensure that there was no stain on normal tissue. Staining intensity was qualitatively scored from 0 (absent) to 3 (strong), and the percentage of tumor cells with nuclear staining was estimated. A sample with more than 15% cells with intensity scored 1 and above was defined as IHC positive.

**Statistical Analysis**—Unless otherwise, specified, all p values were calculated using a two-tailed student's T-Test in Graphpad Prism.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

We wish to thank Drs. Kirsty Sawicka, Pau Creixell, Scott Floyd, Michael Lee, Christian Ellson and all members of the Hemann and Yaffe labs for helpful advice and discussions. We thank the Swanson Biotechnology Center, especially the applied therapeutics and whole animal imaging facility (Scott Malstrom and Milton Cornwall-Brady), flow cytometry facility and the Barbara K. Ostrom Bioinformatics & Computing Facility (Charlie Whittaker) at the Koch Institute / MIT. This work was supported by the Austrian Science Fund (FWF) (J 2900-B21) to S.M., the German Cancer Foundation (Mildred-Scheel Fellowship) to C.J.B, the Damon Runyon Cancer Research Foundation (DRG 2127-12) to K.A.M., Canadian Cancer Society Research Institute grant #020527 to M.S.T., NIH grants (ES015339, GM60594, GM59281, CA112967), the Koch Institute and Center for Environmental Health Sciences Core Grants (P30-CA14051, ES-002109) to M.B.Y. and the Anna Fuller Fund (New Haven, CT) to I.G.C. The authors wish to dedicate this paper to the memory of Officer Sean Collier for his caring service to the MIT.

## References


- Abdelmohsen K, Pullmann R, Lal A, Kim HH, Galban S, Yang X, Blethrow JD, Walker M, Shubert J, Gillespie DA, et al. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. *Mol. Cell.* 2007; 25:543–557. [PubMed: 17317627]
- Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou L-VF, Kolettas E, Niforou K, Zoumpourlis VC, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. *Nature.* 2006; 444:633–637. [PubMed: 17136093]
- Beli P, Lukashchuk N, Wagner SA, Weinert BT, Olsen JV, Baskcomb L, Mann M, Jackson SP, Choudhary C. Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. *Mol. Cell.* 2012:1–14.

- Buck SB, Bradford J, Gee KR, Agnew BJ, Clarke ST, Salic A. Detection of S-phase cell cycle progression using 5-ethynyl-2'-deoxyuridine incorporation with click chemistry, an alternative to using 5-bromo-2'-deoxyuridine antibodies. *BioTechniques*. 2008; 44:927–929. [PubMed: 18533904]
- Cannell IG, Kong YW, Johnston SJ, Chen ML, Collins HM, Dobbyn HC, Elia A, Kress TR, Dickens M, Clemens MJ, et al. p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. *Proc. Natl. Acad. Sci. U.S.A.* 2010; 107:5375–5380. [PubMed: 20212154]
- Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. *Nat Rev Clin Oncol*. 2011; 8:25–37. [PubMed: 20975744]
- Ciccio A, Elledge SJ. The DNA damage response: making it safe to play with knives. *Mol. Cell*. 2010; 40:179–204. [PubMed: 20965415]
- Cuadrado M, Gutierrez-Martinez P, Swat A, Nebreda AR, Fernandez-Capetillo O. p27Kip1 stabilization is essential for the maintenance of cell cycle arrest in response to DNA damage. *Cancer Research*. 2009; 69:8726–8732. [PubMed: 19843869]
- Darnell RB. HITS-CLIP: panoramic views of protein-RNA regulation in living cells. *Wiley Interdisciplinary Reviews. RNA*. 2010; 1:266–286. [PubMed: 21935890]
- Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT. Suppression of Rev3, the catalytic subunit of Pol $\zeta$ , sensitizes drug-resistant lung tumors to chemotherapy. *Proc. Natl. Acad. Sci. U.S.A.* 2010; 107:20786–20791. [PubMed: 21068376]
- Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and  $\beta$ -TrCP: tipping the scales of cancer. *Nature Reviews Cancer*. 2008; 8:438–449. [PubMed: 18500245]
- Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Rothballer A, Ascano M, Jungkamp A-C, Munschauer M, et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. *Cell*. 2010; 141:129–141. [PubMed: 20371350]
- Hsieh FF, Barnett LA, Green WF, Freedman K, Matushansky I, Skoultschi AI, Kelley LL. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase. *Blood*. 2000; 96:2746–2754. [PubMed: 11023508]
- Jackson EL. The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer. *Cancer Research*. 2005; 65:10280–10288. [PubMed: 16288016]
- Jackson SP, Bartek J. The DNA-damage response in human biology and disease. *Nature*. 2009; 461:1071–1078. [PubMed: 19847258]
- Kedde M, Strasser MJ, Boldajipour B, Oude Vrielink JAF, Slanchev K, le Sage C, Nagel R, Voorhoeve PM, van Duijse J, Ørom UA, et al. RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. *Cell*. 2007; 131:1273–1286. [PubMed: 18155131]
- Kedde M, van Kouwenhove M, Zwart W, Oude Vrielink JAF, Elkon R, Agami R. A Pumilio-induced RNA structure switch in p27-3' UTR controls miR-221 and miR-222 accessibility. *Nature Cell Biology*. 2010; 12:1014–1020. [PubMed: 20818387]
- Keene JD, Komisarow JM, Friedersdorf MB. RIP-Chip: the isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts. *Nature Protocols*. 2006; 1:302–307. [PubMed: 17406249]
- Kelland L. The resurgence of platinum-based cancer chemotherapy. *Nature Reviews Cancer*. 2007; 7:573–584. [PubMed: 17625587]
- Liontos M, Velimezi G, Pateras IS, Angelopoulou R, Papavassiliou AG, Bartek J, Gorgoulis VG. The roles of p27Kip1 and DNA damage signalling in the chemotherapy-induced delayed cell cycle checkpoint. *Journal of Cellular and Molecular Medicine*. 2010; 14:2264–2267. [PubMed: 20716117]
- Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, et al. ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage. *Science*. 2007; 316:1160–1166. [PubMed: 17525332]
- Morandell S, Reinhardt HC, Cannell IG, Kim JS, Ruf DM, Mitra T, Couvillon AD, Jacks T, Yaffe MB. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. *Cell Rep*. 2013; 5:868–877. [PubMed: 24239348]

- Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. *Cell*. 2004; 119:847–860. [PubMed: 15607980]
- Paulsen RD, Soni DV, Wollman R, Hahn AT, Yee M-C, Guan A, Hesley JA, Miller SC, Cromwell EF, Solow-Cordero DE, et al. A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. *Mol. Cell*. 2009; 35:228–239. [PubMed: 19647519]
- Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. *Cell*. 1994; 78:59–66. [PubMed: 8033212]
- Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-Deficient Cells Rely on ATM- and ATR-Mediated Checkpoint Signaling through the p38MAPK/MK2 Pathway for Survival after DNA Damage. *Cancer Cell*. 2007; 11:175–189. [PubMed: 17292828]
- Reinhardt HC, Cannell IG, Morandell S, Yaffe MB. Is post-transcriptional stabilization, splicing and translation of selective mRNAs a key to the DNA damage response? *Cell Cycle*. 2011; 10:23–27. [PubMed: 21173571]
- Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt MATM, Wang X, Linding R, Ong S-E, Weaver D, Carr SA, et al. DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization. *Mol. Cell*. 2010; 40:34–49. [PubMed: 20932473]
- Rousseau S, Morrice N, Pegg M, Campbell DG, Gaestel M, Cohen P. Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs. *The EMBO Journal*. 2002; 21:6505–6514. [PubMed: 12456657]
- Shyu AB, Wilkinson MF. The double lives of shuttling mRNA binding proteins. *Cell*. 2000; 102:135–138. [PubMed: 10943833]
- Socinski MA. Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of Standard Treatment Paradigms. *Clinical Cancer Research*. 2004; 10:4210s–4214s. [PubMed: 15217960]
- Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. *Bioinformatics (Oxford, England)*. 2002; 18:207–208.
- Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. *Nature Genetics*. 2004
- Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. *Cell*. 1994; 78:67–74. [PubMed: 8033213]
- Tsao MS, Aviell-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, et al. Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non Small- Cell Lung Cancer. *Journal of Clinical Oncology*. 2007; 25:5240–5247. [PubMed: 18024870]
- Wang Y, Xiao X, Zhang J, Choudhury R, Robertson A, Li K, Ma M, Burge CB, Wang Z. A complex network of factors with overlapping affinities represses splicing through intronic elements. *Nat. Struct. Mol. Biol.* 2013; 20:36–45. [PubMed: 23241926]
- Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Incelet R, Vallieres E, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. *New England Journal of Medicine*. 2005; 352:2589–2597. [PubMed: 15972865]
- Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih IM, Kurman RJ. p53 IHC ovarian cancer. *Modern Pathology*. 2011; 24:1248–1253. [PubMed: 21552211]
- Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, et al. Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*. 2010; 28:4417–4424. [PubMed: 20823422]

### Significance


Platinum-containing regimens are frontline DNA damaging therapies for non-small cell lung cancer (NSCLC), yet the molecular mechanisms that drive resistance to chemotherapy are incompletely understood. Here we show that NSCLC tumors with mutations in *p53* (~50%) are critically dependent on the activity of a post-transcriptional MK2/hnRNPA0 pathway for resistance to chemotherapy. hnRNPA0 regulates both p27<sup>Kip1</sup> and Gadd45 $\alpha$  to enforce cell cycle checkpoints, allowing DNA repair and tolerance to chemotherapy. Analysis of hnRNPA0-target mRNAs in NSCLC patients demonstrates that activity of this pathway correlates with therapeutic response. Thus, pre-screening of patients for the activity of the MK2/hnRNPA0 pathway may predict a sub-population of patients likely to benefit most from chemotherapy.



**Figure 1. A focused screen implicates p27<sup>Kip1</sup> as an hnRNPA0-dependent G1/S regulator**  
**(A)** H1299 cells were depleted of hnRNPA0 or Gadd45α and treated with 2 μM doxorubicin for 4 hr followed by the addition of 250 ng/mL nocodazole for a further 24 hr. Cells were fixed and stained with propidium iodide and analyzed by flow cytometry. Yellow, blue and green arrows depict loss of the G1/S checkpoint in hnRNPA0 knockdown cells but not in Gadd45α knockdown cells. **(B)** Schematic representation of the known role of hnRNPA0 in the DNA damage response. **(C)** Cells were treated with doxorubicin for 16 hr, mRNA levels of the indicated targets were determined by qRT-PCR, and the data represented as fold-

change vs. control siRNA vehicle-treated cells. **(D)** qRT-PCR analysis of H1299 cells, 16 hr post-doxorubicin treatment. Data are represented as fold change vs. control siRNA vehicle-treated cells. Error bars represent mean  $\pm$ SEM, n=3 experiments \*  $p < 0.05$ , \*\*\*  $p < 0.001$ . **(E)** Western blots of H1299 cells 16 hr post-doxorubicin treatment. **(F)** H1299 cells were treated with doxorubicin for 16 hr followed by the addition of cycloheximide. Samples were taken at indicated time points and p27<sup>Kip1</sup> protein levels measured by immuno-blotting. **(G)** H1299 cells were treated with doxorubicin for 16 hr followed by the addition of actinomycin D. At indicated time points p27<sup>Kip1</sup> mRNA levels were determined by qRT-PCR. See also Figure S1.





**Figure 2. p27<sup>Kip1</sup> controls the DNA damage-induced G1/S checkpoint in p53-deficient cells**  
**(A)** Western blots of H1299 cells transfected with p27<sup>Kip1</sup>-specific siRNA or infected with a miR-30-based retroviral p27<sup>Kip1</sup>-specific shRNA (shRNA#1). **(B)** Representative flow cytometry profiles of propidium iodide-stained H1299 cells transfected with a control siRNA or a p27<sup>Kip1</sup>-specific siRNA 16 hr post-doxorubicin treatment. Red arrow indicates loss of the G1 peak in p27<sup>Kip1</sup> depleted cells. **(C)** Quantification of the percentage of G1 arrested cells from 3 independent experiments performed as in panel B. Error bars represent mean  $\pm$  SEM, \*\*\*  $p < 0.001$ . **(D, E)** Example of a typical EdU labeling experiment is shown in D. In panel E, loss of p27<sup>Kip1</sup> causes entry into S-phase despite the presence of DNA damage in a manner and magnitude comparable to that of hnRNPA0 knockdown. Quantified EdU incorporation assays were performed in H1299 cells transfected with a p27<sup>Kip1</sup>-specific siRNA or transduced with a p27<sup>Kip1</sup> or hnRNPA0-specific shRNA retrovirus, at 15-16 hr following application of 1  $\mu$ M doxorubicin. EdU incorporation values were normalized to those of control undamaged cells treated with vehicle alone (Fig S2B-


C). Bars represent mean % of positive cells relative to vehicle treated cells (see Fig S2B)  $\pm$  SEM, n=3 experiments. \*  $p < 0.05$ .  
See also Figure S2.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 3. MK2-mediated phosphorylation of hnRNP A0 in response to DNA damage induces binding to its target RNAs and cytoplasmic localization**


(A) Schematic representation of hnRNP A0 domain architecture and sequence surrounding Serine-84 in the linker region between the two RNA recognition motifs (RRMs). The MK2 phosphorylated residue, Serine-84, is highlighted in red. (B) Western blots of H1299 cells transfected with a control shRNA or an MK2-specific shRNA and treated with vehicle or doxorubicin. (C) qRT-PCR analysis of cells treated as in (B). (D) Stable H1299 cell lines harboring HA-tagged WT hnRNP A0 or a Ser-84-to-Ala mutant were treated with doxorubicin for 16 hr followed by HA-immuno-precipitation. Co-precipitated RNA was

subjected to qRT-PCR for p27<sup>Kip1</sup> and Gadd45 $\alpha$  mRNAs. Data shown as fold-change vs. the WT untreated control. Error bars represent mean  $\pm$  SEM, n=2 independent experiments.

**(E)** Nuclear-cytoplasmic fractionation of H1299 cells following 16 hr doxorubicin treatment.

**(F)** Immuno-flourescence microscopy of H1299 cells fixed 16 hr after 2  $\mu$ M doxorubicin treatment. Scale bar represents 5  $\mu$ m. **(G)** Quantification of hnRNPA0 localization immuno-flourescence from two independent experiments, error bars represent mean  $\pm$  SEM.

See also Figure S3.



**Figure 4. Synthetic lethality between hnRNPA0-loss and a defective p53 pathway in response to chemotherapy**

(A,B) H1299 (*p53* null) cells were transfected with a control or hnRNPA0-specific siRNA and treated with doxorubicin or cisplatin as indicated, followed by western blotting for cleaved caspase 3. Data are represented as fold-change vs control siRNA vehicle-treated cells. Error bars represent mean  $\pm$  SEM, n=3 experiments. \*  $p < 0.05$  \*\*  $p < 0.01$  \*\*\*  $p < 0.001$  (C) *K-Ras<sup>G12D</sup>;p53<sup>-/-</sup>* KP7B murine lung adenocarcinoma cells were transduced with a miR-30 retrovirus expressing an hnRNPA0-specific shRNA and treated as indicated. (D) A panel of *p53* mutant and WT cell lines were transduced or transfected with hnRNPA0-targeting shRNA or siRNA and cell death in response to cisplatin assayed by measuring cleaved caspase 3. Shown is fold change in cell death in cisplatin treated hnRNPA0-knockdown cells relative to cisplatin treated control siRNA/shRNA cells. Bars represent mean  $\pm$  SEM n=3-5. \*  $p < 0.05$ . (E) Heatmap representation of  $\text{Log}_2$  fold change in the

mRNA levels of the indicated p53-target genes after 16 hr of 10  $\mu$ M cisplatin treatment. Lower panel is a p53 western blot of the indicated cell lines treated or not with 10  $\mu$ M cisplatin for 16 hr. **(F)** p53 levels from untreated cells from **(E)** were normalized to beta-actin,  $\text{Log}_2$  transformed, and plotted against the  $\text{Log}_2$  transformed data from **(D)**. Shown is the linear regression and the pearson  $R^2$ . **(G)** p53 WT H1944 cells were transfected with the indicated siRNAs for 48 hr followed by treatment with 10  $\mu$ M cisplatin for 24 hr and measurement of cleaved caspase 3. Bars represent mean  $\pm$  SEM n=3. \* p = < 0.05. See also Figure S4.


Author Manuscript

Author Manuscript

Author Manuscript


Author Manuscript






**Figure 5. Decreased hnRNPA0 activity promotes cisplatin efficacy against p53-defective non-small cell lung cancer (NSCLC) *in vivo***

(A) Schematic representation of the transplantable NSCLC model. (B) Representative bioluminescence images before and after cisplatin treatment on Day 0 and 7. Red arrows indicate timing of cisplatin dosing. (C) Quantification of lung bio-luminescence pre-treatment and 5 days post-cisplatin treatment. Error bars represent mean  $\pm$  SEM, 3-4 animals per condition \*  $p < 0.05$ . (D) Post-treatment Kaplan-Meier survival analysis of control tumor-bearing mice with or without cisplatin treatment, as indicated. (Vector  $n=7$ , vector + Cis  $n=7$ ). (E) Post-treatment Kaplan-Meier survival analysis of shA0 tumor-bearing mice with or without cisplatin treatment, as indicated. (shA0(3)  $n=7$ , shA0(3) + Cis  $n=9$ ).  $p$  values in D and E were calculated using the log-rank test. See also Figure S5.



**Figure 6. hnRNPA0 promotes resistance to chemotherapy through p27<sup>Kip1</sup> and Gadd45 $\alpha$**   
**(A)** Model depicting the role of MK2, hnRNPA0, p27<sup>Kip1</sup> and Gadd45 $\alpha$  in the DNA damage response, limiting the efficacy of anti-cancer chemotherapy. **(B)** H1299 (*p53* null) cells were transfected with the indicated siRNAs and analyzed as in (Figure 4). Error bars represent mean  $\pm$  SEM, n=3 experiments. \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , n.s.=not significant. Control siRNA data from Figure 4B are shown again here for comparison. **(C, D)** Stage II patients from the JBR.10 lung cancer adjuvant chemotherapy trial were clustered into two groups based on expression of both p27<sup>Kip1</sup> and Gadd45 $\alpha$ . Patients in this trial were either observed (Obs, orange line) or treated with cisplatin/vinorelbine-based chemotherapy (Chemo, green line). Kaplan-Meier analysis of lung cancer patients based on expression of MK2/hnRNPA0-target mRNAs demonstrates that only those patients with low levels of these mRNAs benefit significantly from adjuvant chemotherapy. HR=hazard ratio, 95% CI=95% confidence interval. p values were calculated using the log-rank test. See also Figure S6.



**Figure 7. The primary p53/p21 axis actively suppresses the successor hnRNPA0**  
**(A)** *p53* WT A549 cells were transfected with a control siRNA or a p53-targeting siRNA for 48 hr, followed by treatment with 2  $\mu$ M doxorubicin for 24 hr. hnRNPA0 protein expression was measured by western blotting. Data are plotted as fold-change in hnRNPA0 protein (normalized to actin) relative to vehicle-treated control siRNA transfected cells, bars represent mean  $\pm$  SEM, n=3 experiments. \*\*  $p < 0.01$ . **(B)** *p53* WT A549 cells were transfected with siRNAs as in (A), then treated with 10  $\mu$ M MDM-2 inhibitor/p53 activator Nutlin 3a for 24 hr. Left panel: data are plotted as fold-change in hnRNPA0 protein

(normalized to actin) relative to vehicle-treated control siRNA transfected cells, bars represent mean  $\pm$  SEM, n=4 experiments. \*  $p < 0.05$ . Right panel, data are plotted as fold-change in hnRNPA0 mRNA relative to vehicle-treated control siRNA transfected cells, bars represent mean  $\pm$  SEM, n=3 experiments. \*\*  $p < 0.01$ . **(C)** A549 cells were treated as in **(B)** except that at 24 hr Actinomycin D was added to the culture medium and time points taken for RNA analysis by qRT-PCR. Data represent percent remaining hnRNPA0 mRNA for each condition relative to the 24 hr time point where Actinomycin was added. **(D)** Slopes of the lines from 3 independent experiments performed as in **(C)** were calculated and used to determine the fold change in mRNA half-life upon p53 activation. Bars represent mean  $\pm$  SEM. **(E)** A549 cells were transfected with a control siRNA or a p21-targeting siRNA for 48 hr, followed by treatment with 10  $\mu$ M Nutlin 3a for 24 hr. p21 and hnRNPA0 mRNA expression were measured by qRT-CPR. Data are plotted as fold-change in mRNA levels relative to vehicle-treated control siRNA transfected cells, bars represent mean  $\pm$  SEM, n=3 experiments. \*  $p < 0.05$ , \*\*  $p < 0.01$ . **(F)** Model representation of the interplay between the p53 and MK2/hnRNPA0 pathways in response to DNA damaging chemotherapy. See also figure S7.

**Table 1**Association of p27<sup>kip1</sup>/Gadd45 $\alpha$  expression with clinical factors in stage II NSCLC patients.

		Expression of p27 and GADD45 $\alpha$		
		High (% , n=30)	Low (% , n=30)	p value
Histology	ADC	16 (55.2)	13 (44.8)	0.725
	SQCC	12 (44.4)	15 (55.6)	
	LCUC	2 (50.0)	2 (50.0)	
Chemotherapy	OBS	18 (64.3)	10 (35.7)	0.038
	ACT	12 (37.5)	20 (62.5)	
Age (year)	<65	26 (49.1)	27 (50.9)	0.688
	65	4 (57.1)	3 (42.9)	
Sex	Male	24 (53.3)	21 (46.7)	0.371
	Female	6 (40.0)	9 (60.0)	
P53 IHC *	Negative	11 (44.0)	14 (56.0)	0.571
	Positive	14 (51.9)	13 (48.1)	
	Unknown	5 (62.5)	3 (37.5)	

\* Negative is used as a surrogate of wild type p53, positive as a surrogate of p53 with missense mutation